Navigation Links
22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey
Date:7/10/2009

c therapeutic agents to regulate the biological mechanisms of mental disorders, i.e. the neuronal interactions that give rise to these disorders. For this purpose, neuropsychopharmacology investigates the effect of drugs on the central nervous system (CNS) and their use in treating disorders such as anxiety, mania, depression, schizophrenia, dementia or neurological and addictive disorders in the most rational and empirical manner.

Neuropsychopharmacological research provides data that are required to develop drugs, which act on specific receptors within a neurotransmitter system. The pharmacological progress achieved in recent decades is mainly due to the development of receptor-specific drugs. For instance, the currently most commonly used antidepressant drugs, the SSRIs, selectively inhibit the transport of the neurotransmitter serotonin, prolonging its activity in the synapse between the nerve cells. In the next step, the development of receptor subtype-specific drugs is currently encouraged. So-called hyperselective drugs are thought to allow the direct targeting of specific sites of relevant neural activity, thereby maximising the efficacy of the drug within the clinical target and minimising adverse events. For instance, the signalling of serotonin is mediated by 14 receptor subtypes. As one of the main mediators of the neurotransmitter action the serotonin (1A) subtype is of particular interest, since evidence indicates that it is a target for novel therapeutic advances in several neuropsychiatric disorders (gren et al., 2008). Furthermore, cognitive and neural mechanisms involved in emotion processing can be manipulated pharmacologically, and research continues to identify novel targets for anxiolytic drugs (Garner et al., 2009).

New developments in neuropsychopharmacology may lead to targeted treatment options for a wide variety of mental disorders.

European College of Neuropsychopharmacology (ECNP)

The Europ
'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
431-405-5734
European College of Neuropsychopharmacology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. 22nd Congress of the European College of Neuropsychopharmacology
2. CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda
3. World Congress on Osteoporosis 2010 presents outstanding scientific program
4. Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress
5. World Congress on Osteoporosis 2010 -- IOFWCO-ECCEO10 to be held in Florence
6. 17th Annual Congress on Womens Health convenes
7. Less than one month to opening of world’s largest global congress on osteoporosis
8. Nutrition and bone health session to open the IOF World Congress on Osteoporosis in Bangkok
9. Take advantage of reduced pre-registration rates for the IOF World Congress on Osteoporosis
10. IOF World Congress on Osteoporosis in Bangkok to address Asian issues
11. INCF organizes the first congress dedicated to the emerging field of neuroinformatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... International Liver CongressTM 2013 has demonstrated the, accuracy of ... Non Alcoholic Fatty Liver disease (NAFLD) comprises two ... relatively benign and one group with NASH which may ... the only means of distinguishing the two was to ...
... 23, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... assurance software products, today reported financial results for its first ... the first quarter of 2013 was $5.6 million, an increase ... last year. Operating income before patent related income in the ...
... April 23, 2013 Governor Tom Corbett ... with its 2013 BIO Governor of the Year Award in ... and public health sectors within Pennsylvania . ... BIO International Convention in Chicago, Ill. ...
Cached Biology News:Aware, Inc. Reports First Quarter 2013 Financial Results 2Aware, Inc. Reports First Quarter 2013 Financial Results 3Aware, Inc. Reports First Quarter 2013 Financial Results 4Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 2Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 3
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Positive results from Pyratine XR(TM) rosacea-specific study also slated ... March 8, 2009 - NAPA, Calif., March 5 ... sciences company engaged in the development of technologies that ... Pyratine XR(TM) is officially launching at the American Academy ...
... the launch of a suite of miRNA functional ... vector based precursor miRNA expression clones; 2) miTarget(TM) ... 3) All-in-One(TM) miRNA RT-qPCR system.Constructed in a lentiviral ... collections cover all known miRNAs for human ...
... 5 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology therapies, today announced that it will hold ... quarter and year-end financial results and provide a ... the Company,s lead product candidate.Jerry McMahon, Ph.D., chairman ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
Biology Products: